Indication: Pharmacokinetics

A phase II/III, open-label, multicenter, safety, efficacy and pharmacokinetic study of Dexmedetomidine in neonates ages >28 weeks to <44 weeks gestational age.

Sub-indication: Pharmacokinetics

Drug Study

Principal Investigator: Dan Stewart, M.D.
Norton Children's Neonatology, affiliated with the UofL School of Medicine

Sponsor: Hospira, Inc.

Search our entire site.